AGENUS INC Costs and Expenses
AGENUS INC (AGEN) reported Costs and Expenses of $23.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-07
- AGENUS INC costs and expenses for the quarter ending 2026-06-30 was $23.23M, a 45.23% decline year-over-year.
- AGENUS INC costs and expenses for the quarter ending 2026-03-31 was $18.68M, a 50.02% decline year-over-year.
- AGENUS INC costs and expenses for the quarter ending 2025-06-30 was $42.40M.
- AGENUS INC costs and expenses for the quarter ending 2025-03-31 was $37.38M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month |
|---|---|---|
| 2026-06-30 | $23.23M 10-Q · filed 2026-08-07 | $41.91M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $18.68M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $42.40M 10-Q · filed 2026-08-07 | $79.78M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $37.38M 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |